Bellevue's Paul Major: Healthcare stocks unlikely to be impacted by second Trump presidency

Speaking during a roundtable event in London last week, Major said Trump would likely take a softer stance on antitrust regulation, allowing for more mergers and acquisitions in the healthcare sector, and has refused to argue in favour of curtailing entitlement programmes. "Under a Trump presidency, there could be more excitement and appetite for M&A activity involving potential targets among small or mid-cap biotechs and healthcare programmes," he said. "This could drive out performance in this segment relative to large or mega-cap companies." Despite this, the Bellevue fund manager ...